Mechanisms and consequences of complement activation during hemodialysis.

[1]  J. Zubeldia,et al.  Murine eosinophils and IL-1: alpha IL-1 mRNA detection by in situ hybridization. Production and release of IL-1 from peritoneal eosinophils. , 1990, Journal of immunology.

[2]  M. Kazatchkine,et al.  Regulation of the human alternative complement pathway: formation of a ternary complex between factor h, surface‐bound c3b and chemical groups on nonactivating surfaces , 1989, European journal of immunology.

[3]  J. Cavaillon,et al.  In vivo induction of interleukin-1 during hemodialysis. , 1989, Kidney international.

[4]  A. Cheung,et al.  Analysis of the complement C3 fragments associated with hemodialysis membranes. , 1989, Kidney international.

[5]  M. Kazatchkine,et al.  Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. , 1988, Biomaterials.

[6]  M. Kazatchkine,et al.  Relative inefficiency of terminal complement activation. , 1988, Journal of immunology.

[7]  D. Hazuda,et al.  The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta. , 1988, The Journal of biological chemistry.

[8]  M. Kazatchkine,et al.  The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. , 1988, Molecular immunology.

[9]  J. Cavaillon,et al.  C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. , 1987, Journal of immunology.

[10]  M. Pangburn.  Mechanism of recognition of alternative pathway activators analysis using c3b bound low molecular weight polysaccharides of defined structure , 1987 .

[11]  T. Balstad,et al.  Dialyzer Generation and Plasma Clearance of Activated Complement during Hemodialysis , 1986 .

[12]  A. Cheung,et al.  Cardiopulmonary effects of cuprophane-activated plasma in the swine. , 1986, Kidney international.

[13]  C. Dinarello,et al.  Human interleukin-1 production during hemodialysis. , 1986, Nephron.

[14]  H. Colten,et al.  Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1 , 1985, The Journal of experimental medicine.

[15]  H. Colten,et al.  Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. , 1985, The New England journal of medicine.

[16]  S. Durum,et al.  Interleukin 1: an immunological perspective. , 1985, Annual review of immunology.

[17]  C. Dinarello.  Interleukin-1 and the pathogenesis of the acute-phase response. , 1984, The New England journal of medicine.

[18]  F. Port,et al.  Complement activation and hypersensitivity reactions to dialysis membranes. , 1984, The New England journal of medicine.

[19]  D. Chenoweth.  Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. , 1984, Artificial organs.

[20]  J. Cavaillon,et al.  Interleukin 1 secretion by human monocytes stimulated by the isolated polysaccharide region of the Bordetella pertussis endotoxin. , 1984, Molecular immunology.

[21]  A. Cheung,et al.  Anaphylatoxin formation during hemodialysis: comparison of new and re-used dialyzers. , 1983, Kidney international.

[22]  A. Cheung,et al.  Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. , 1983, Kidney international.

[23]  F. Port,et al.  Pyrogen and Endotoxin Reactions during Hemodialysis1 , 1983 .

[24]  L. Henderson,et al.  Hemodialysis Hypotension: The Interleukin Hypothesis , 1983 .

[25]  M. Kazatchkine,et al.  The human alternative complement pathway: biology and immunopathology of activation and regulation. , 1982, Progress in allergy.

[26]  C. Dinarello,et al.  Molecular basis of fever in humans. , 1982, The American journal of medicine.

[27]  M. Kazatchkine,et al.  The Human Alternative Complement Pathway : Biology and Immunopathology of Activation and Regulation1 , 1982 .

[28]  D. Fearon,et al.  IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. , 1981, Journal of immunology.

[29]  S. Ruddy,et al.  The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. , 1981, Journal of immunology.

[30]  L. Henderson.  Symptomatic hypotension during hemodialysis. , 1980, Kidney international.

[31]  E. Lowrie,et al.  Effect of dialyzer reuse on leukopenia, hypoxemia and total hemolytic complement system. , 1980, Transactions - American Society for Artificial Internal Organs.

[32]  R S Kronenberg,et al.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. , 1977, The New England journal of medicine.

[33]  P. Robinson,et al.  Pyrexial Reactions during Haemodialysis , 1971, British medical journal.